Artificial Intelligence In Digital Genome
Artificial intelligence in digital genomics involves the application of AI technologies, such as machine learning, deep learning, and natural language processing, to the analysis and interpretation of genomic data. AI helps decode vast amounts of genetic information to identify disease patterns and mutations, predict individual responses to treatments, and advance personalized medicine. By leveraging AI, researchers and clinicians can accelerate genetic research, improve the accuracy of diagnoses, and develop targeted therapies, ultimately transforming the field of genomics and enhancing our understanding of complex genetic structures and functions.
Needs and Benefits of AI in Digital Genome:
The rising need to reduce costs and time in drug discovery is anticipated to fuel the growth of the global artificial intelligence in digital genome market during the forecast period. Developing new drugs is typically a lengthy, complex, and expensive endeavor, necessitating alternative methods to streamline the process. Traditional drug discovery and development, often carried out through in vivo and in vitro methods, are both costly and time-consuming. By increasingly incorporating artificial intelligence into drug discovery, significant savings in both time and expenses can be achieved. Consequently, this trend is expected to drive market growth in the coming years.
The global artificial intelligence in the digital genome market is expected to grow significantly due to increased investments in AI genomics. For example, in July 2021, Deep Genomics, an AI therapeutics company, secured $180 million in Series C funding to enhance its AI discovery platform for programmable RNA therapeutics and expand its clinical portfolio. This funding round was led by Soft Bank Vision Fund 2, with participation from new investors such as the Canadian Pension Plan Investment Board, Alexandria Venture Investments, Khosla Ventures, Fidelity Management & Research Company, Amplitude Ventures, Magnetic Ventures, and True Ventures.
Challenges and Opportunities:
Recommended by LinkedIn
The most recent outbreak of the coronavirus COVID-19 began in Wuhan, China, on December 31, 2019. The World Health Organization (WHO) declared it a pandemic on March 11, 2020. As of October 4, 2021, the WHO's Weekly Epidemiological Update reported over 234,809,103 cases and 4,800,375 deaths worldwide. COVID-19 impacts the economy in three primary ways: directly affecting production and demand, disrupting distribution channels, and financially impacting firms and markets. Nationwide lockdowns in countries like China, India, Saudi Arabia, UAE, and Egypt have hindered drug transportation. Supplying raw materials for drug manufacturing has also been challenging due to transport disruptions. Additionally, the surge in COVID-19 cases has led to erratic product demand from retailers. The pandemic has significantly boosted the medical device manufacturing industry, increasing sales of diagnostic tests, masks, gowns, gloves, and other devices used to treat or diagnose COVID-19.
The global artificial intelligence in the digital genome market faces significant growth challenges due to a shortage of skilled AI professionals and unclear regulatory guidelines for medical software. AI systems are complex and require a workforce proficient in areas like cognitive computing, machine learning, deep learning, and image recognition. For example, personnel managing AI systems must have expertise in these domains. Additionally, integrating AI solutions into existing systems is difficult and requires extensive data processing to mimic human brain functions. Even minor errors can lead to system failures or undesirable outcomes, making the process even more challenging.
Leading Players in the market:
IBM Watson leverages AI to analyze genetic data, providing insights into disease mechanisms and potential treatments. Their AI-driven solutions assist in identifying genetic mutations and recommending personalized therapies.
NVIDIA provides powerful AI computing platforms that support genomics research. Their GPUs and AI frameworks accelerate the analysis of large genomic datasets, enabling faster and more accurate discoveries.
Artificial intelligence involves replicating human intelligence by machines, particularly computer systems. A digital genome represents the entirety of genetic material in a cell or organism in a digital format. This approach simplifies the collection of data related to chronic diseases, allowing experts to closely examine genetic issues. The use of AI in the digital genome field aims to develop computer systems capable of tasks like genome mapping.